论文部分内容阅读
已知1型人类免疫缺陷症病毒（HIV-1）包膜糖蛋白含有诱导T细胞记忆的表位,能够诱生抗包膜糖蛋白中和抗体、其他功能性抗体及抗HIV-1细胞毒性T细胞（CTL）应答。研究证实重组包膜糖蛋白能在健康人中诱导这些形式的体液和细胞免疫应答,然而疫苗诱导的中和抗体对实验室适应株有很强的活性,抗HIV-1CTL活性不太强。作者评价了含有HIV-1_(MN)株包膜糖蛋白（MNrgp160）氨基酸序列的候选rgp160疫苗的安全性和免疫原性。
It is known that type 1 human immunodeficiency virus (HIV-1) envelope glycoproteins contain epitopes that induce T cell memory and are capable of inducing anti-envelope glycoprotein neutralizing antibodies, other functional antibodies, and anti-HIV-1 cytotoxicity T cell (CTL) response. Studies have demonstrated that recombinant envelope glycoproteins induce these forms of humoral and cellular immune responses in healthy individuals, whereas vaccine-induced neutralizing antibodies have strong activity against laboratory-adapted strains and are less aggressive against HIV-1 CTLs. The authors evaluated the safety and immunogenicity of the candidate rgp160 vaccine containing the amino acid sequence of the HIV-1_ (MN) envelope glycoprotein (MNrgp160).